A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Daiichi Sankyo, Inc.

Open source

DOI
10.25934/00007337
Published
2021
Container
Not recorded
Publisher
Vivli
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.25934/00007337,
  title = {A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath},
  author = {Daiichi Sankyo, Inc.},
  year = {2021},
  doi = {10.25934/00007337},
  url = {https://doi.org/10.25934/00007337}
}

RIS

TY  - JOUR
TI  - A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath
AU  - Daiichi Sankyo, Inc.
PY  - 2021
DO  - 10.25934/00007337
UR  - https://doi.org/10.25934/00007337
ER  - 

APA

Inc., D. S. (2021). A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath. https://doi.org/10.25934/00007337

Source records